Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Hydrazine sulfate in nonsmall-cell lung cancer.

Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

Serum response heterogeneity among nonsmall cell lung cancer cell lines.

DDP human hepatic cancer cell line.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology.

Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer.

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.

Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.

Effectiveness of maintenance treatments for nonsmall cell lung cancer.

Refining the treatment of advanced nonsmall cell lung cancer.

Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins.

MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin.

Therapeutic management of ALK+ nonsmall cell lung cancer patients.

Suggest Documents

First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer.

The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Hydrazine sulfate in nonsmall-cell lung cancer.

Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.

Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.

Serum response heterogeneity among nonsmall cell lung cancer cell lines.

DDP human hepatic cancer cell line.

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients.

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology.

Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.

S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial.

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer.

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer.

EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.

Determinants of drug response in a cisplatin-resistant human lung cancer cell line.

MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.

Effectiveness of maintenance treatments for nonsmall cell lung cancer.

Refining the treatment of advanced nonsmall cell lung cancer.

Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins.

MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin.

Therapeutic management of ALK+ nonsmall cell lung cancer patients.

Reversal of cisplatin resistance with amphotericin B in a non-small cell lung cancer cell line.

Recommend Documents

Follow Us